We detected prostate cancer ISUP 2 or higher diagnosis in 8% and 47% of men with LP/P BRCA1 and BRCA2 variants, respectively, compared to the IMPACT study showing ISUP 2 or higher diagnosis in 45% and 63% of men with BRCA1 and BRCA2 variants, respectively. The gene discussed is BRCA2; the disease is prostate cancer.